

ECONOMIC ANALYSIS AFTER THE INCORPORATION OF BEVACIZUMAB BIOSIMILAR IN A THIRD LEVEL HOSPITAL

Infante Camarero A., Gutierrez Fernandez I., Vicente Gonzalez B., De Frutos del Pozo M., Sanchez Luque L.



Servicio de Farmacia, Hospital Universitario de Burgos

BACKGROUND AND OBJECTIVE



- The introduction of biosimilars after the end of the patenting of biologics is an opportunity for significant savings in pharmaceutical spending, contributing to the sustainability of the health system.
- The objective was to estimate the economic savings achieved by switching to bevacizumab biosimilar in a third level hospital

MATERIAL AND METHODS

- A descriptive observational study was conducted during 2019 to estimate the economic impact of the incorporation of bevacizumab biosimilar, one of the objectives of the Annual Management Plan of our Autonomous Community, Castilla y León.
- **Variables collected:** number of patients, total annual cost, quarterly cost variation 2019/2020.
- To estimate the cost (€), the net unit price was used (PVL - Discounts (official and laboratory) + 4% VAT) and the Farmatools® application was used to obtain the data

RESULTS

JULY-SEPTEMBER 2019	
Nº patients treated with original bevacizumab	n= 50
Total amount	194,54 €

SWITCH A BIOSIMILAR
(July 2020)


JULY-SEPTEMBER 2020	
Nº patients treated with original bevacizumab	n= 58
Total amount	119,00 €

The cost was reduced by 38.8%



- ✓ **Degree of penetration of 96.7%** in the Oncology Service
- ✓ 2 patients (3.3%) did not switch to biosimilarity because their indication was not included in the technical data sheet.

TOTAL ANNUAL AMOUNT 2019-2020



- **In 2019**, a total of 121 patients were treated with the original bevacizumab, for a total annual amount of 945,710€ and an annual expense/patient of 7,816€.
- **In 2020**, assuming a cost reduction of **38.8%** and the same number of patients treated as in 2019 (121 patients), annual expenditure is estimated at 578,891€ and a **saving of 366,819€ per year.**

CONCLUSIONES

- The introduction of biosimilars is a very efficient measure to reduce hospital pharmaceutical expenses, maintaining the same effectiveness and safety as with the use of the original medicine, contributing to the sustainability of the National Health System.